36 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
approach for hematologic malignancies.”
“IDHIFA® is an innovative, targeted treatment that has benefited numerous AML patients who may otherwise have had … , a biotechnology company that stands out for its strong scientific foundation and a track record of successful development of multiple innovative
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
29 Jun 18
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License
4:06pm
diseases, and CStone Pharmaceuticals, a privately-held biopharmaceutical company devoted to developing a new generation of innovative drugs, today … to the development of innovative drugs. With a broad pipeline, the company engages in the development of cancer therapeutics with a special focus on immuno
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Regulation FD Disclosure
7:04am
Exhibit 99.1
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business … in oncology and further supports our commitment to provide innovative treatments to cancer patients with unmet medical needs. It is a key step for the Servier
DEFA14A
EX-99.1
AGIO
Agios Pharmaceuticals Inc
21 Dec 20
Additional proxy soliciting materials
7:10am
Exhibit 99.1
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business … in oncology and further supports our commitment to provide innovative treatments to cancer patients with unmet medical needs. It is a key step for the Servier
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
12 Jan 15
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120
12:00am
commitment to innovative therapeutics in cancer metabolism,” said Thomas Daniel, M.D., president of research & early development at Celgene. “The progress
8-K
EX-99.1
fdf xkwe3s64zgsca
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
8-K
EX-99.1
s7fhv0mmv 537b
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
8-K
EX-99.1
6equl3944rs6v7v3
12 Jul 22
Agios Appoints Brian Goff as Chief Executive Officer
4:14pm
8-K
EX-99.1
icoy9sidj yk2fj9tyd7
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
8-K
EX-99.1
hwxscc 691
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
8-K
EX-99.1
5s206
11 Jun 21
Other Events
7:24am
8-K
EX-99.1
c784uh08ct qo
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am
DEFA14A
tsdwvedtw8lioy0p9
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
lbo5gqu95
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.2
qa9 gzmcvvd
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
DEFA14A
24cn05o2y
12 Jan 21
Additional proxy soliciting materials
5:15pm
S-1
EX-10.13
r50vmllcygrqc3
10 Jun 13
IPO registration
12:00am